These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1532 related articles for article (PubMed ID: 18025205)

  • 1. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.
    Pallandre JR; Brillard E; Créhange G; Radlovic A; Remy-Martin JP; Saas P; Rohrlich PS; Pivot X; Ling X; Tiberghien P; Borg C
    J Immunol; 2007 Dec; 179(11):7593-604. PubMed ID: 18025205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
    Brillard E; Pallandre JR; Chalmers D; Ryffel B; Radlovic A; Seilles E; Rohrlich PS; Pivot X; Tiberghien P; Saas P; Borg C
    Exp Hematol; 2007 Mar; 35(3):416-25. PubMed ID: 17309822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT3 promotes bone fracture healing by enhancing the FOXP3 expression and the suppressive function of regulatory T cells.
    Sun G; Wang Z; Ti Y; Wang Y; Wang J; Zhao J; Qian H
    APMIS; 2017 Aug; 125(8):752-760. PubMed ID: 28493494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen-dependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation.
    Albert MH; Liu Y; Anasetti C; Yu XZ
    Eur J Immunol; 2005 Sep; 35(9):2598-607. PubMed ID: 16078276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.
    Elpek KG; Yolcu ES; Franke DD; Lacelle C; Schabowsky RH; Shirwan H
    J Immunol; 2007 Dec; 179(11):7295-304. PubMed ID: 18025172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G protein-coupled receptor 83 overexpression in naive CD4+CD25- T cells leads to the induction of Foxp3+ regulatory T cells in vivo.
    Hansen W; Loser K; Westendorf AM; Bruder D; Pfoertner S; Siewert C; Huehn J; Beissert S; Buer J
    J Immunol; 2006 Jul; 177(1):209-15. PubMed ID: 16785516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.
    Chen W; Jin W; Hardegen N; Lei KJ; Li L; Marinos N; McGrady G; Wahl SM
    J Exp Med; 2003 Dec; 198(12):1875-86. PubMed ID: 14676299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4
    Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET
    J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Requirement of CD28 signaling in homeostasis/survival of TGF-beta converted CD4+CD25+ Tregs from thymic CD4+CD25- single positive T cells.
    Liu Y; Amarnath S; Chen W
    Transplantation; 2006 Oct; 82(7):953-64. PubMed ID: 17038912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
    Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
    J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets.
    Pyzik M; Piccirillo CA
    J Leukoc Biol; 2007 Aug; 82(2):335-46. PubMed ID: 17475784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-27 inhibits the development of regulatory T cells via STAT3.
    Huber M; Steinwald V; Guralnik A; Brüstle A; Kleemann P; Rosenplänter C; Decker T; Lohoff M
    Int Immunol; 2008 Feb; 20(2):223-34. PubMed ID: 18156621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice.
    Carrier Y; Yuan J; Kuchroo VK; Weiner HL
    J Immunol; 2007 Jan; 178(1):179-85. PubMed ID: 17182553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4
    Peixoto TV; Carrasco S; Botte DAC; Catanozi S; Parra ER; Lima TM; Ugriumov N; Soriano FG; de Mello SBV; Rodrigues CM; Goldenstein-Schainberg C
    Adv Rheumatol; 2019 Jul; 59(1):30. PubMed ID: 31340848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo.
    Delgado M; Chorny A; Gonzalez-Rey E; Ganea D
    J Leukoc Biol; 2005 Dec; 78(6):1327-38. PubMed ID: 16204628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Foxp3 expression in CD4
    Zhu XW; Zhu HZ; Zhu YQ; Feng MH; Qi J; Chen ZF
    J Huazhong Univ Sci Technolog Med Sci; 2016 Oct; 36(5):677-682. PubMed ID: 27752897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis.
    Sugimoto N; Oida T; Hirota K; Nakamura K; Nomura T; Uchiyama T; Sakaguchi S
    Int Immunol; 2006 Aug; 18(8):1197-209. PubMed ID: 16772372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease.
    Laurence A; Amarnath S; Mariotti J; Kim YC; Foley J; Eckhaus M; O'Shea JJ; Fowler DH
    Immunity; 2012 Aug; 37(2):209-22. PubMed ID: 22921119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming growth factor-beta1-induced CD4+CD25+ regulatory T cells in vitro reverse and prevent a murine lupus-like syndrome of chronic graft-versus-host disease.
    Su H; Ye DQ; Wang BL; Fang XH; Chen J; Wang Q; Li WX; Zhang N
    Br J Dermatol; 2008 Jun; 158(6):1197-209. PubMed ID: 18410422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma.
    Liyanage UK; Goedegebuure PS; Moore TT; Viehl CT; Moo-Young TA; Larson JW; Frey DM; Ehlers JP; Eberlein TJ; Linehan DC
    J Immunother; 2006; 29(4):416-24. PubMed ID: 16799337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.